Cirrhotic and Non-cirrhotic Patients With Clinically Significant Portal Hypertension
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study ID
- NCT07405749
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cirrhosis, Liver
- Clinically Significant Portal Hypertension(CSPH)
- Gastroesophageal Varices
- Portal Hypertension
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Alterations in conventional coagulation tests in patients with cirrhosis and/or portal hypertension do not reliably predict bleeding risk, as hemostatic balance is complex and often compensated. Many procedure-related bleeding events are driven by non-coagulatory factors, such as portal hypertension or technical aspects of the procedure. Most commonly performed procedures carry a low risk of bleeding even in the presence of elevated INR or thrombocytopenia, and no validated laboratory thresholds support prophylactic correction. Risk assessment should therefore be based on procedural factors, severity of liver disease, and systemic patient conditions, with correction of modifiable risk factors particularly before high-risk elective procedures.
Key Dates
- First listed
- Feb 12, 2026
- Start date
- Feb 28, 2026
- Status verified
- Feb 2026
- Primary completion
- Feb 28, 2029
- Completion
- Feb 28, 2030
Study Design
- Enrollment
- 2,500 participants (estimated)
Primary Outcome Measure
Incidence of Bleeding and Adverse Events in CSPH Patients Undergoing Elective Procedures [ Time Frame: 36-48 months ]
Central Contacts
- Francesco PI Santopaolo3492754288
- Elisabetta SC Creta3480778584
Related Studies
- Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in CirrhosisRecruiting · The Cleveland Clinic · Cleveland, Ohio
- Erlotinib for Hepatocellular Carcinoma ChemopreventionPHASE2 · Not Yet Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in CirrhosisPHASE4 · Recruiting · Mercy Medical Center · Baltimore, Maryland
- Danazol for Treatment of Cytopenias in Patients With CirrhosisPHASE2 · Recruiting · University of Southern California · Los Angeles, California